Revlimid is a medication used to treat types of multiple myeloma, mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma, and anemia in myelodysplastic syndromes (MDS) in adults. Revlimid helps to slow cancer growth, block new blood vessel growth in tumors, and help the immune system fight cancer. Revlimid is available as capsules that are taken once a daily.
Revlimid received FDA approval on December 27, 2005. The active ingredient, sometimes called the generic name, is lenalidomide.
This medicine is only available through a restricted distribution program called the Lenalidomide REMS program, as it may cause birth defects or embryo-fetal death.